Hikma's ANDA for Solriamfetol Hydrochloride Receives Approval Status
Hikma's ANDA218016 for Solriamfetol Hydrochloride has received an Approval Pending status from the FDA.
Published: June 23, 2026
Updated: June 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Wakefulness Promoting Agent
Company: Hikma
Asset: Solriamfetol Hydrochloride
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Hikma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Hikma's ANDA for Solriamfetol Hydrochloride receiving Approval Pending status signals a potential shift in the competitive landscape for wakefulness promoting agents. This could impact pricing and market share for existing products in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the final approval decision and potential launch timelines for Hikma's product.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.